Principal Investigator
David Kerman
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20201171
Clinical Trial Summary
AbbVie M20-259 A Phase 3, Multicenter, Randomized, Efficacy Assessor-Blinded Study of Risankizumab Compared to Ustekinumab for the Treatment of Adult Subjects With Moderate to Severe Crohn's Disease Who Have Failed Anti-TNF therapy.
Phase
Phase II/III
Funding Agency/Sponsor
Industry
Disease
Gastrointestinal, Stomach, Esophageal
Contact Information
Study Contact
Niurka Colina
Phone Number
+1 (305) 2436405
Email
nxc610@miami.edu